What David Sinclair's Longevity Protocol Would Cost Outside a Celebrity Context

By
Published Updated Last reviewed
Prescription access and medication affordability image for What David Sinclair's Longevity Protocol Would Cost Outside a Celebrity Context

What David Sinclair Has Publicly Confirmed

David Sinclair is a professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. In his 2019 book Lifespan: Why We Age and Why We Don't Have To, Sinclair disclosed that he personally takes NMN (nicotinamide mononucleotide), metformin, and resveratrol on a daily basis. He has repeated these disclosures in numerous public appearances, including episodes of The Joe Rogan Experience (January 2019, January 2021), interviews with 60 Minutes Australia, and his own podcast Lifespan with Dr. David Sinclair.

In a widely cited interview segment on The Joe Rogan Experience, Sinclair stated he takes 1 gram of NMN each morning mixed with yogurt, 1 gram of resveratrol also dissolved in fat (typically olive oil or yogurt), and 800 mg of metformin at night. He has described this regimen as his personal choice, not a clinical recommendation.

Sinclair's academic work centers on sirtuins and NAD+ biology, which provides the theoretical basis for his supplement choices. He has also co-founded companies in the longevity space, including Life Biosciences and Tally Health, a fact he discloses publicly when discussing his research.

At a glance

  • Celebrity: David Sinclair, Ph.D., Harvard geneticist and aging researcher
  • Status: Publicly confirmed personal use of NMN, metformin, and resveratrol in his book Lifespan and across dozens of podcast and media appearances
  • Drug family: Longevity (NAD+ precursors, biguanides, polyphenols)
  • Key question: What would this protocol actually cost a regular patient, and can you get insurance to cover any of it?

The Three Compounds: Clinical Profiles and Pricing

NMN (Nicotinamide Mononucleotide)

NMN is a precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in hundreds of metabolic processes. Sinclair's own laboratory published foundational work showing that NMN supplementation restores NAD+ levels and reverses age-related physiological decline in mice. A 2022 randomized controlled trial in Science demonstrated that NMN increased NAD+ levels in human muscle tissue and improved insulin sensitivity in prediabetic women, though sample sizes remain small.

NMN is sold as a dietary supplement, not a prescription drug. The FDA briefly raised questions about NMN's regulatory status in late 2022, and as of mid-2025, it remains available over the counter in most formulations. Quality varies dramatically between brands.

Cost realities:

  • Reputable third-party-tested NMN (1 g/day): $40 to $150 per month depending on brand and purity certification
  • Brands with published Certificates of Analysis (e.g., ProHealth, Renue by Science, DoNotAge) tend to cluster at $60 to $100/month for a 1 g daily dose
  • No insurance coverage exists. NMN is classified as a supplement and cannot be billed under any pharmacy benefit
  • Bulk powder is cheaper ($0.80 to $1.50 per gram) than capsules ($2 to $5 per gram equivalent)

Metformin (Off-Label for Longevity)

Metformin is FDA-approved for type 2 diabetes. Its potential longevity benefits stem from observational data, including a 2014 study in Diabetes, Obesity and Metabolism that found diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls. The proposed mechanisms include AMPK activation, mTOR inhibition, and reduced inflammatory signaling.

The TAME (Targeting Aging with Metformin) trial, a landmark study designed to test metformin specifically as an aging intervention, received IND approval from the FDA and has been enrolling participants. Results are pending.

A clinically relevant caveat: a 2019 study in Aging Cell found that metformin blunted exercise-induced improvements in muscle mitochondrial respiration and cardiorespiratory fitness in older adults. For patients who exercise intensely, this tradeoff deserves discussion with a prescriber.

Cost realities:

  • Generic metformin (500 to 1000 mg/day): $4 to $15/month at retail pharmacy, often on $4 generic lists at major chains
  • The drug itself is cheap. The barrier is the prescription
  • Most physicians will not prescribe metformin for longevity to a patient with normal glucose and A1c. Off-label prescribing is legal but not incentivized by payers
  • Telehealth longevity clinics (AgelessRx, Push Health, and similar) charge $50 to $150 for a consultation and will prescribe off-label metformin. This consultation fee is not covered by insurance
  • Some patients report success getting a prescription by presenting borderline-high fasting glucose (100 to 125 mg/dL) to a primary care physician, though the HealthRX Medical Team does not endorse manufacturing a diagnostic justification

Resveratrol

Resveratrol is a polyphenol found in grape skins, red wine, and berries. Sinclair's early work showed that resveratrol activates SIRT1 and extends lifespan in obese mice. Translation to humans has been less clear. A 2015 meta-analysis in Clinical Nutrition found modest improvements in fasting glucose and insulin levels in diabetic subjects, but a large trial in healthy older adults showed no significant effect on cardiovascular biomarkers.

Bioavailability is a persistent challenge. Oral resveratrol undergoes extensive first-pass metabolism, and plasma levels after a 1 g dose remain low. Sinclair has stated publicly that he takes resveratrol with fat to improve absorption, which aligns with published pharmacokinetic data.

Cost realities:

  • Trans-resveratrol (1 g/day): $20 to $60/month for powder; capsule forms at this dose run higher
  • No insurance coverage. Classified as a supplement
  • Purity matters: some products contain primarily cis-resveratrol, which has lower biological activity. Third-party testing is the only reliable quality check

Total Monthly Cost: Three Scenarios

The HealthRX Medical Team modeled three spending tiers for a patient attempting the publicly described Sinclair regimen (1 g NMN, 800 mg metformin, 1 g resveratrol daily).

Budget tier (bulk powders, generic metformin via PCP): $65 to $85/month. This assumes the patient already has a primary care relationship, can obtain an off-label metformin prescription without a specialty consultation, and is comfortable sourcing NMN and resveratrol as bulk powder from vendors with published third-party testing.

Mid-range tier (capsule-form supplements from established brands, telehealth metformin): $130 to $200/month. Includes a quarterly telehealth consultation fee amortized monthly ($15 to $40/month equivalent) and name-brand NMN and resveratrol in capsule form.

Premium tier (concierge longevity clinic with labs): $250 to $400+/month. This includes a concierge or functional medicine physician who monitors bloodwork (NAD+ metabolites, liver function, glucose, inflammatory markers) quarterly, pharmaceutical-grade supplements, and the metformin prescription. Some clinics bundle these into membership fees.

None of these tiers include insurance reimbursement for the supplements. Metformin is the only component with any potential for insurance coverage, and only if the prescribing indication is type 2 diabetes or prediabetes.

What Insurance Will and Won't Cover

The American healthcare system was not designed with longevity protocols in mind. Here is what a patient navigating this regimen should expect.

Covered (with appropriate diagnosis): Metformin, if prescribed for diabetes or prediabetes (ICD-10 E11.x or R73.03). Copay: $0 to $10 in most plans.

Not covered, no exceptions: NMN, resveratrol, and any other dietary supplement. These cannot be billed under pharmacy benefits regardless of the prescriber's rationale.

Gray area: Bloodwork. If a physician orders metabolic panels, A1c, lipids, and inflammatory markers as part of a wellness protocol, some plans cover these under preventive care. If the same labs are ordered by a cash-pay longevity clinic, the patient pays out of pocket ($200 to $500 per panel at commercial lab pricing, or $30 to $80 via direct-to-consumer lab services).

HSA/FSA eligibility: Metformin with a prescription qualifies. Supplements do not unless a physician writes a Letter of Medical Necessity, which is rarely accepted for longevity-only indications.

The HealthRX Medical Team's Clinical Take

Sinclair's public transparency about his regimen has done something unusual: it put specific compounds with real mechanisms of action into mainstream conversation. That is different from a celebrity endorsing a branded supplement. NMN, metformin, and resveratrol each have published preclinical and early clinical data supporting their investigation as longevity interventions.

The gap between "scientifically interesting" and "clinically proven for healthy humans" remains wide. The National Institute on Aging explicitly cautions that no supplement has been proven to slow aging in humans. The TAME trial for metformin may change this calculus, but results are not yet available.

For a non-celebrity patient, the cost barrier is real but not insurmountable. At $75 to $200/month, this protocol is less expensive than many prescription regimens. The harder barrier is clinical guidance. Most primary care physicians are not equipped to discuss NAD+ biology, and longevity-focused clinicians operate largely outside insurance networks. Patients often end up self-prescribing based on podcast content, which carries its own risks, particularly around drug interactions (metformin and contrast dye, resveratrol and anticoagulants) and appropriate monitoring.

The HealthRX Medical Team's position: if you are considering this protocol, the supplement costs are the easy part. The harder and more valuable investment is finding a physician who will monitor your labs, screen for contraindications, and adjust the regimen based on your individual metabolic profile rather than a one-size-fits-all protocol described in a book.

Frequently asked questions

›
›
›
›
›
›

References

  • Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016. https://pubmed.ncbi.nlm.nih.gov/27127236/
  • Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2022. https://pubmed.ncbi.nlm.nih.gov/35441588/
  • Bannister CA, et al. Can people with type 2 diabetes live longer than those without? Diabetes Obes Metab. 2014. https://pubmed.ncbi.nlm.nih.gov/25041462/
  • Kulkarni AS, et al. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 2020. https://pubmed.ncbi.nlm.nih.gov/31405774/
  • Konopka AR, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019. https://pubmed.ncbi.nlm.nih.gov/30548390/
  • Baur JA, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006. https://pubmed.ncbi.nlm.nih.gov/17086191/
  • Hausenblas HA, et al. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus. Mol Nutr Food Res. 2015. https://pubmed.ncbi.nlm.nih.gov/25455573/
  • Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014. https://pubmed.ncbi.nlm.nih.gov/29184669/
  • Rajman L, et al. Therapeutic potential of NAD-boosting molecules. Cell Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/30651639/